Literature DB >> 16533217

Prodromal bullous pemphigoid.

Philina M Lamb1, Edward Abell, Michael Tharp, Roy Frye, Jau-Shyong Deng.   

Abstract

BACKGROUND: Prodromal bullous pemphigoid (PBP) can be difficult to diagnose. Early recognition in its early stages may decrease the morbidity and progression of the disease. Clinical presentations and current treatments available for PBP will be described.
METHODS: A retrospective review was performed on 53 patients diagnosed with PBP.
RESULTS: Overall, the average disease duration of PBP was 11.8 months. The average age of presentation of PBP was 70.8 years. The most common presentations were urticaria-like plaques (67.9%), eczema-like lesions (11.3%), and dermatitis herpetiformis-like lesions (9.4%). The majority of patients responded well to low doses of systemic corticosteroids, tetracycline, and/or high potency topical corticosteroids.
CONCLUSIONS: Patients with PBP tend to be in their sixth or early seventh decade of life and, on average, the duration of disease is 1 year. The most common presentation of disease is urticaria-like plaques.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533217     DOI: 10.1111/j.1365-4632.2004.02457.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  11 in total

1.  Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 2.  Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.

Authors:  Minhee Kim; Luca Borradori; Dédée F Murrell
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

3.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

4.  Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis.

Authors:  Xin-Xing Jin; Xue Wang; Ying Shan; Si-Zhe Li; Qun Xu; Hong-Zhong Jin; Ya-Gang Zuo
Journal:  Arch Dermatol Res       Date:  2021-03-28       Impact factor: 3.017

5.  A 17-year-old woman with bullous lesions.

Authors:  Maria Crisan; Razvan Bucur; Diana Crisan
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

Review 6.  The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations.

Authors:  Khalaf Kridin; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2018-08-20

7.  Bullous eczema presenting as bullous pemphigoid-like eruption: A case series.

Authors:  George Atteh; Emily F Cole; Adam J Perricone; Ron J Feldman
Journal:  JAAD Case Rep       Date:  2021-02-07

8.  Bullous Pemphigoid Exacerbated by Radiation Therapy: An Atypical Presentation.

Authors:  Rachel Choi; Shawn Cowper; Melissa Young; Jonathan Leventhal
Journal:  Adv Radiat Oncol       Date:  2021-09-10

Review 9.  A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Authors:  Adriana T Lopez; Larisa Geskin
Journal:  Oncologist       Date:  2018-07-17

Review 10.  Interventions for bullous pemphigoid: An updated systematic review of randomized clinical trials.

Authors:  Ali Asilian; Hoda Safaei; Fariba Iraji; Farahnaz Fatemi Naeini; Gita Faghihi; Fatemeh Mokhtari
Journal:  Med J Islam Repub Iran       Date:  2021-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.